175 related articles for article (PubMed ID: 37248319)
1. Model for predicting prognosis and immunotherapy based on CD
Bao W; Song Z; Wan H; Yu X; Chen Z; Jiang Y; Chen X; Le K
J Cancer Res Clin Oncol; 2023 Sep; 149(12):9839-9855. PubMed ID: 37248319
[TBL] [Abstract][Full Text] [Related]
2. A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma.
Kroesen M; Nierkens S; Ansems M; Wassink M; Orentas RJ; Boon L; den Brok MH; Hoogerbrugge PM; Adema GJ
Int J Cancer; 2014 Mar; 134(6):1335-45. PubMed ID: 24038106
[TBL] [Abstract][Full Text] [Related]
3. The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology.
Wienke J; Dierselhuis MP; Tytgat GAM; Künkele A; Nierkens S; Molenaar JJ
Eur J Cancer; 2021 Feb; 144():123-150. PubMed ID: 33341446
[TBL] [Abstract][Full Text] [Related]
4. PTPRO-related CD8
Dong H; Xie C; Yao Z; Zhao R; Lin Y; Luo Y; Chen S; Qin Y; Chen Y; Zhang H
Front Immunol; 2022; 13():947841. PubMed ID: 36003382
[TBL] [Abstract][Full Text] [Related]
5. Co-expression of receptor tyrosine kinases and CD8 T-lymphocyte genes is associated with distinct prognoses, immune cell infiltration patterns and immunogenicity in cancers.
Long J; Chen P; Yang X; Bian J; Yang X; Wang A; Lin Y; Wang H; Sang X; Zhao H
Transl Res; 2023 Jun; 256():14-29. PubMed ID: 36586534
[TBL] [Abstract][Full Text] [Related]
6. Integrated single-cell and bulk sequencing analyses with experimental validation identify the prognostic and immunological implications of CD226 in pan-cancer.
Ma P; Sun W
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14597-14617. PubMed ID: 37580402
[TBL] [Abstract][Full Text] [Related]
7. Establishment and Validation of a Prognostic Immune Signature in Neuroblastoma.
Yu Y; Zeng Y; Xia X; Zhou JG; Cao F
Cancer Control; 2021; 28():10732748211033751. PubMed ID: 34569303
[TBL] [Abstract][Full Text] [Related]
8. Low Expression of IL-15 and NKT in Tumor Microenvironment Predicts Poor Outcome of MYCN-Non-Amplified Neuroblastoma.
Liao YM; Hung TH; Tung JK; Yu J; Hsu YL; Hung JT; Yu AL
J Pers Med; 2021 Feb; 11(2):. PubMed ID: 33668573
[TBL] [Abstract][Full Text] [Related]
9. Construction and validation of immune-related LncRNAs classifier to predict prognosis and immunotherapy response in laryngeal squamous cell carcinoma.
Wang X; Pan Y; Ou Y; Duan T; Zou Y; Zhou X
World J Surg Oncol; 2022 May; 20(1):164. PubMed ID: 35606755
[TBL] [Abstract][Full Text] [Related]
10. Single-cell transcriptomics reveals a low CD8
Peng YL; Xiong LB; Zhou ZH; Ning K; Li Z; Wu ZS; Deng MH; Wei WS; Wang N; Zou XP; He ZS; Huang JW; Luo JH; Liu JY; Jia N; Cao Y; Han H; Guo SJ; Dong P; Yu CP; Zhou FJ; Zhang ZL
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35121646
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch.
Cornel AM; Dunnebach E; Hofman DA; Das S; Sengupta S; van den Ham F; Wienke J; Strijker JGM; van den Beemt DAMH; Essing AHW; Koopmans B; Engels SAG; Lo Presti V; Szanto CS; George RE; Molenaar JJ; van Heesch S; Dierselhuis MP; Nierkens S
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36521927
[TBL] [Abstract][Full Text] [Related]
12. Advances in chimeric antigen receptor immunotherapy for neuroblastoma.
Heczey A; Louis CU
Discov Med; 2013 Dec; 16(90):287-94. PubMed ID: 24333408
[TBL] [Abstract][Full Text] [Related]
13. Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma.
Bao R; Spranger S; Hernandez K; Zha Y; Pytel P; Luke JJ; Gajewski TF; Volchenboum SL; Cohn SL; Desai AV
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34272305
[TBL] [Abstract][Full Text] [Related]
14. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
15. Infiltration by Intratumor and Stromal CD8 and CD68 in Cervical Cancer.
Dimitrova P; Vasileva-Slaveva M; Shivarov V; Hasan I; Yordanov A
Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109686
[No Abstract] [Full Text] [Related]
16. Exploration of the molecular characteristics of the tumor-immune interaction and the development of an individualized immune prognostic signature for neuroblastoma.
Jin W; Zhang Y; Liu Z; Che Z; Gao M; Peng H
J Cell Physiol; 2021 Jan; 236(1):294-308. PubMed ID: 32510620
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral CXCL13
Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
[TBL] [Abstract][Full Text] [Related]
18. A novel EIF3C-related CD8
Li R; Wang Y; Wen X; Cheng B; Lv R; Chen R; Hu W; Wang Y; Liu J; Lin B; Zhang H; Zhang E; Tang X
J Cancer Res Clin Oncol; 2024 Feb; 150(2):103. PubMed ID: 38400862
[TBL] [Abstract][Full Text] [Related]
19. A meta-validated immune infiltration-related gene model predicts prognosis and immunotherapy sensitivity in HNSCC.
Ding Y; Chu L; Cao Q; Lei H; Li X; Zhuang Q
BMC Cancer; 2023 Jan; 23(1):45. PubMed ID: 36639648
[TBL] [Abstract][Full Text] [Related]
20. Prediction of prognosis, immunogenicity and efficacy of immunotherapy based on glutamine metabolism in lung adenocarcinoma.
Liu J; Shen H; Gu W; Zheng H; Wang Y; Ma G; Du J
Front Immunol; 2022; 13():960738. PubMed ID: 36032135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
